Drug LitigationActos Patients: The One Year Mark & Cumulative Exposure

May 20, 2012

Type 2 diabetes patients should be aware that the U.S. Food and Drug Administration (FDA) has warned that the use of Actos (pioglitazone), a prominent diabetes medication, for longer than one year has been linked to a notably increased risk of bladder cancer. In fact, although the one year mark is important, the FDA has also noted that the correlation between treatment and cancer risk is perhaps more closely tied to cumulative pioglitazone exposure. As the one year mark approaches, cumulative exposure for most patients tends to near a kind of tipping point in which bladder cancer risk dramatically rises.

 

Are you ready to find out more about the risks of bladder cancer and Actos (pioglitazone), one of its possible causes? This isn’t simply a medical issue for some patients, but a legal issue, too. Find out what your first steps need to be by contacting the attorneys and professionals at the law firm of Nachawati Law Group today.  

———

About Nachawati Law Group
Nachawati Law Group represents parties in mass tort litigation, businesses and governmental entities in contingent litigation, and individuals in complex personal injury litigation. For more information, visit contact [email protected] or call 214-890-0711.

https://ntrial.com/ntrial/wp-content/uploads/Nachawati-Law-logo-White-2-160x25.png

©2025 Nachawati Law Group           Terms and Conditions | Privacy Policy